Alea Delmastro

Alea Delmastro

Auto-generated profile, based on publicly available information

Alea Delmastro

Department of Pathology, Stanford University School of Medicine, Stanford, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2022 in Nature Immunology
Verified
Journal Article
Open access
PDF file
EMErin F. McCaffrey
Erin F. McCaffrey
MDMichele Donato
Michele Donato
LKLeeat Keren
Leeat Keren
ZCZhenghao Chen
Zhenghao Chen
ADAlea Delmastro
Alea Delmastro
MAMichael Angelo
Michael Angelo
Tuberculosis (TB) in humans is characterized by formation of immune-rich granulomas in infected tissues, the architecture and composition of which are thought to affect disease outcome. However, our understanding of the spatial relationships that control human granulomas is limited. Here, we used multiplexed ion beam imaging by time of flight (MIBI-TOF) to image 37 proteins in tissues from patients with active TB. We constructed a comprehensive atlas that maps 19 cell subsets across 8 spatial microenvironments. This atlas shows an IFN-γ-depleted microenvironment enriched for TGF-β, regulatory T cells and IDO1+ PD-L1+ myeloid cells. In a further transcriptomic meta-analysis of peripheral blood from patients with TB, immunoregulatory trends mirror those identified by granuloma imaging. Notably, PD-L1 expression is associated with progression to active TB and treatment response. These data indicate that in TB granulomas, there are local spatially coordinated immunoregulatory programs with systemic manifestations that define active TB.

23 February 2026 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
EMErin F. McCaffrey
Erin F. McCaffrey
ADAlea C. Delmastro
Alea C. Delmastro
IFIsobel Fitzhugh
Isobel Fitzhugh
JRJolene S. Ranek
Jolene S. Ranek
SDSarah Douglas
Sarah Douglas
MAMichael Angelo
Michael Angelo

23 February 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
EMErin F. McCaffrey
Erin F. McCaffrey
ADAlea C. Delmastro
Alea C. Delmastro
IFIsobel Fitzhugh
Isobel Fitzhugh
JRJolene S. Ranek
Jolene S. Ranek
SDSarah Douglas
Sarah Douglas
MAMichael Angelo
Michael Angelo
SUMMARY: Despite being heavily infiltrated by immune cells, tuberculosis (TB) granulomas often subvert the host response to Mycobacterium tuberculosis (Mtb) infection and support bacterial persistence. We previously discovered that human TB granulomas are enriched for immunosuppressive factors typically associated with tumor-immune evasion, raising the intriguing possibility that they promote tolerance to infection. In this study, our goal was to identify the prime drivers for establishing this tolerogenic niche and to determine if the magnitude of this response correlates with bacterial persistence. To do this, we conducted a multimodal spatial analysis of 52 granulomas from 16 non-human primates (NHP) who were infected with low dose Mtb for 9-12 weeks. Notably, each granuloma’s bacterial burden was individually quantified allowing us to directly ask how granuloma spatial structure and function relate to infection control. We found that a universal feature of TB granulomas was partitioning of the myeloid core into two distinct metabolic environments, one of which is hypoxic. This hypoxic environment associated with pathologic immune cell states, dysfunctional cellular organization of the granuloma, and a near-complete blockade of lymphocyte infiltration that would be required for a successful host response. The extent of these hypoxia-associated features correlated with worsened bacterial burden. We conclude that hypoxia governs immune cell state and organization within granulomas and is a potent driver of subverted immunity during TB.

18 February 2026 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
NGNoah F. Greenwald
Noah F. Greenwald
INIris Nederlof
Iris Nederlof
CSCameron Sowers
Cameron Sowers
DDDaisy Yi Ding
Daisy Yi Ding
SPSeongyeol Park
Seongyeol Park
MAMichael Angelo
Michael Angelo

25 August 2023 in EBioMedicine
Verified
Journal Article
Open access
AKAdam S. Kirosingh
Adam S. Kirosingh
ADAlea Delmastro
Alea Delmastro
AKAbel Kakuru
Abel Kakuru
KPKattria van der Ploeg
Kattria van der Ploeg
SBSanchita Bhattacharya
Sanchita Bhattacharya
PJPrasanna Jagannathan
Prasanna Jagannathan
Malaria in pregnancy (MIP) causes higher morbidity in primigravid compared to multigravid women; however, the correlates and mechanisms underlying this gravidity-dependent protection remain incompletely understood. We aimed to compare the cellular immune response between primigravid and multigravid women living in a malaria-endemic region and assess for correlates of protection against MIP. We characterised the second trimester cellular immune response among 203 primigravid and multigravid pregnant women enrolled in two clinical trials of chemoprevention in eastern Uganda, utilizing RNA sequencing, flow cytometry, and functional assays. We compared responses across gravidity and determined associations with parasitaemia during pregnancy and placental malaria. Using whole blood RNA sequencing, no significant differentially expressed genes were identified between primigravid (n = 12) and multigravid (n = 11) women overall (log 2(FC) > 2, FDR < 0.1). However, primigravid (n = 49) women had higher percentages of malaria-specific, non-naïve CD4+ T cells that co-expressed IL-10 and IFNγ compared with multigravid (n = 85) women (p = 0.000023), and higher percentages of these CD4+ T cells were associated with greater risks of parasitaemia in pregnancy (Rs = 0.49, p = 0.001) and placental malaria (p = 0.0073). These IL-10 and IFNγ co-producing CD4+ T cells had a genomic signature of Tr1 cells, including expression of transcription factors cMAF and BATF and cell surface makers CTLA4 and LAG-3. Malaria-specific Tr1 cells were highly prevalent in primigravid Ugandan women, and their presence correlated with a higher risk of malaria in pregnancy. Understanding whether suppression of Tr1 cells plays a role in naturally acquired gravidity-dependent immunity may aid the development of new vaccines or treatments for MIP. This work was funded by NIH (PO1 HD059454, U01 AI141308, U19 AI089674, U01 AI155325, U01 AI150741), the March of Dimes (Basil O'Connor award), and the Bill and Melinda Gates Foundation (OPP 1113682).

11 March 2022 in Nature Immunology
Verified
Journal Article
Open access
PDF file
EMErin F. McCaffrey
Erin F. McCaffrey
MDMichele Donato
Michele Donato
LKLeeat Keren
Leeat Keren
ZCZhenghao Chen
Zhenghao Chen
ADAlea Delmastro
Alea Delmastro
MAMichael Angelo
Michael Angelo